Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies
Shots:
- Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally, it is eligible to receive upto $660M in future clinical, regulatory and commercial milestone payments along with royalties based upon the w/w sales after receiving a $25M milestone
- Jounce led the development of JTX-1811 through IND clearance, and thereafter Gilead has exclusive rights to develop and commercialize the program
- JTX-1811 is a mAb, targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells
Click here to read full press release/ article | Ref: Globe Newswire | Image: Real Money- The Street